A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Active:	No
Cancer Type:	Gynecologic Cancers Ovarian Cancer Primary Peritoneal Cancer Unknown Primary	NCT ID:	NCT03522246
Trial Phases:	Phase III	Protocol IDs:	CO-338-087/GOG-3020/ENGOT-ov45 (primary) NCI-2018-01248
Eligibility:	18 Years and older, Female	Study Type:	Treatment
Study Sponsor:	zr Pharma & GmbH
NCI Full Details:	http://clinicaltrials.gov/show/NCT03522246

Summary

This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm
study evaluating rucaparib and nivolumab as maintenance treatment following response to
front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will
be analyzed based on homologous recombination (HR) status of tumor samples.

Treatment Sites in Georgia

Atlanta Gynecologic Oncology
980 Johnson Ferry Road
Suite 900
Atlanta, GA 30342
404-303-3355
www.geraldfeuer.com

Doctors:

Gerald A. Feuer MD

Georgia Gynecologic Oncology
980 Johnson Ferry Road
Suite 910
Atlanta, GA 30342
404-303-3355
www.ggo-atl.com/

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

Study Coordinator:

Jen Cuvo
404-236-8304

Doctors:

Gerald A. Feuer MD

Guilherme Cantuaria MD

Meaghan Tenney MD

University Gynecologic Oncology
960 Johnson Ferry Road
Suite 130
Atlanta, GA 30342
404-303-3355
www.ugynonc.com

Doctors:

Oi Stephanie Yap MD, FACOG

Guilherme Cantuaria MD

Benedict B. Benigno MD

Meaghan Tenney MD

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.